Association between Antacid Exposure and Risk of Interstitial Lung Diseases
BACKGROUND: The mechanisms leading to lung fibrosis are still under investigation. This study aimed to demonstrate whether antacids could prevent the development of interstitial lung disease (ILD).
METHODS: This population-based longitudinal cohort study was conducted between January 2006 and December 2010 in South Korea. Eligible subjects were ≥40 years of age, exposed to proton pump inhibitors (PPI)±histamine-2 receptor antagonists (H-2 blockers) or H-2 blockers only, and had no history of ILD between 2004 and 2005. Exposure to antacids was defined as the administration of either PPI or H-2 receptor antagonists for >14 days, whereas underexposure was defined as antacid treatment administered for less than 14 days. Newly developed ILDs, including idiopathic pulmonary fibrosis (IPF), were counted during the 5-year observation period. The association between antacid exposure and ILD development was evaluated using adjusted Cox regression models with variables, such as age, sex, smoking history, and comorbidities.
RESULTS: The incidence rates of ILD with/without antacid use were 43.2 and 33.8/100,000 person-years, respectively and those of IPF were 14.9 and 22.9/100,000 person-years, respectively. In multivariable analysis, exposure to antacid before the diagnosis of ILD was independently associated with a reduced development of ILD (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45 to 0.71; p<0.001), while antacid exposure was not associated with development of IPF (HR, 0.88; 95% CI, 0.72 to 1.09; p=0.06).
CONCLUSION: Antacid exposure may be independently associated with a decreased risk of ILD development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
Tuberculosis and respiratory diseases - 87(2024), 2 vom: 18. Apr., Seite 185-193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bae, Soohyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antacid Exposure |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4046/trd.2023.0093 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366017942 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366017942 | ||
| 003 | DE-627 | ||
| 005 | 20240405233312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4046/trd.2023.0093 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM366017942 | ||
| 035 | |a (NLM)38111098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bae, Soohyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between Antacid Exposure and Risk of Interstitial Lung Diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: The mechanisms leading to lung fibrosis are still under investigation. This study aimed to demonstrate whether antacids could prevent the development of interstitial lung disease (ILD) | ||
| 520 | |a METHODS: This population-based longitudinal cohort study was conducted between January 2006 and December 2010 in South Korea. Eligible subjects were ≥40 years of age, exposed to proton pump inhibitors (PPI)±histamine-2 receptor antagonists (H-2 blockers) or H-2 blockers only, and had no history of ILD between 2004 and 2005. Exposure to antacids was defined as the administration of either PPI or H-2 receptor antagonists for >14 days, whereas underexposure was defined as antacid treatment administered for less than 14 days. Newly developed ILDs, including idiopathic pulmonary fibrosis (IPF), were counted during the 5-year observation period. The association between antacid exposure and ILD development was evaluated using adjusted Cox regression models with variables, such as age, sex, smoking history, and comorbidities | ||
| 520 | |a RESULTS: The incidence rates of ILD with/without antacid use were 43.2 and 33.8/100,000 person-years, respectively and those of IPF were 14.9 and 22.9/100,000 person-years, respectively. In multivariable analysis, exposure to antacid before the diagnosis of ILD was independently associated with a reduced development of ILD (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45 to 0.71; p<0.001), while antacid exposure was not associated with development of IPF (HR, 0.88; 95% CI, 0.72 to 1.09; p=0.06) | ||
| 520 | |a CONCLUSION: Antacid exposure may be independently associated with a decreased risk of ILD development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antacid Exposure | |
| 650 | 4 | |a Idiopathic Pulmonary Fibrosis | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Interstitial Lung Disease | |
| 700 | 1 | |a Loloci, Gjustina |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Dong Yoon |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Hye Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Jihyeon |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Won-Il |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberculosis and respiratory diseases |d 2012 |g 87(2024), 2 vom: 18. Apr., Seite 185-193 |w (DE-627)NLM222134194 |x 1738-3536 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2024 |g number:2 |g day:18 |g month:04 |g pages:185-193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4046/trd.2023.0093 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2024 |e 2 |b 18 |c 04 |h 185-193 | ||